155 related articles for article (PubMed ID: 26988296)
21. Effects of direct Renin inhibition on myocardial fibrosis and cardiac fibroblast function.
Zhi H; Luptak I; Alreja G; Shi J; Guan J; Metes-Kosik N; Joseph J
PLoS One; 2013; 8(12):e81612. PubMed ID: 24349097
[TBL] [Abstract][Full Text] [Related]
22. Direct renin inhibition with aliskiren protects against myocardial ischemia/reperfusion injury by activating nitric oxide synthase signaling in spontaneously hypertensive rats.
Zhang W; Han Y; Meng G; Bai W; Xie L; Lu H; Shao Y; Wei L; Pan S; Zhou S; Chen Q; Ferro A; Ji Y
J Am Heart Assoc; 2014 Jan; 3(1):e000606. PubMed ID: 24473199
[TBL] [Abstract][Full Text] [Related]
23. Impaired post-infarction cardiac remodeling in chronic kidney disease is due to excessive renin release.
Ogawa M; Suzuki J; Takayama K; Senbonmatsu T; Hirata Y; Nagai R; Isobe M
Lab Invest; 2012 Dec; 92(12):1766-76. PubMed ID: 22986786
[TBL] [Abstract][Full Text] [Related]
24. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat.
Habibi J; Whaley-Connell A; Hayden MR; DeMarco VG; Schneider R; Sowers SD; Karuparthi P; Ferrario CM; Sowers JR
Endocrinology; 2008 Nov; 149(11):5643-53. PubMed ID: 18653711
[TBL] [Abstract][Full Text] [Related]
25. Aliskiren inhibits the renin-angiotensin system in retinal pigment epithelium cells.
Simão S; Santos DF; Silva GA
Eur J Pharm Sci; 2016 Sep; 92():22-7. PubMed ID: 27343695
[TBL] [Abstract][Full Text] [Related]
26. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
[TBL] [Abstract][Full Text] [Related]
27. Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice.
Choi DE; Jeong JY; Lim BJ; Chang YK; Na KR; Shin YT; Lee KW
J Urol; 2011 Aug; 186(2):694-701. PubMed ID: 21683401
[TBL] [Abstract][Full Text] [Related]
28. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats.
Feldman DL; Jin L; Xuan H; Contrepas A; Zhou Y; Webb RL; Mueller DN; Feldt S; Cumin F; Maniara W; Persohn E; Schuetz H; Jan Danser AH; Nguyen G
Hypertension; 2008 Jul; 52(1):130-6. PubMed ID: 18490518
[TBL] [Abstract][Full Text] [Related]
29. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
30. The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice.
Pöss J; Werner C; Lorenz D; Gensch C; Böhm M; Laufs U
Basic Res Cardiol; 2010 Nov; 105(6):725-35. PubMed ID: 20857126
[TBL] [Abstract][Full Text] [Related]
31. Dynamic observation of mechanically-injured mouse femoral artery reveals an antiinflammatory effect of renin inhibitor.
Ino J; Kojima C; Osaka M; Nitta K; Yoshida M
Arterioscler Thromb Vasc Biol; 2009 Nov; 29(11):1858-63. PubMed ID: 19778947
[TBL] [Abstract][Full Text] [Related]
32. Aliskiren Regulates Neonatal Fc Receptor and IgG Metabolism with Attenuation of Anti-GBM Glomerulonephritis in Mice.
Kang JH; Baik HW; Yoo SM; Kim JH; Cheong HI; Park CG; Kang HG; Ha IS
Nephron; 2016; 134(4):272-282. PubMed ID: 27560625
[TBL] [Abstract][Full Text] [Related]
33. Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity.
Stucchi P; Cano V; Ruiz-Gayo M; Fernández-Alfonso MS
Br J Pharmacol; 2009 Oct; 158(3):771-8. PubMed ID: 19694726
[TBL] [Abstract][Full Text] [Related]
34. Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren.
Schefe JH; Neumann C; Goebel M; Danser J; Kirsch S; Gust R; Kintscher U; Unger T; Funke-Kaiser H
J Hypertens; 2008 Sep; 26(9):1787-94. PubMed ID: 18698213
[TBL] [Abstract][Full Text] [Related]
35. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide.
Feldt S; Batenburg WW; Mazak I; Maschke U; Wellner M; Kvakan H; Dechend R; Fiebeler A; Burckle C; Contrepas A; Jan Danser AH; Bader M; Nguyen G; Luft FC; Muller DN
Hypertension; 2008 Mar; 51(3):682-8. PubMed ID: 18212269
[TBL] [Abstract][Full Text] [Related]
36. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells.
Batenburg WW; de Bruin RJ; van Gool JM; Müller DN; Bader M; Nguyen G; Danser AH
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1151-7. PubMed ID: 18388329
[TBL] [Abstract][Full Text] [Related]
37. Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin.
Chung S; Kim S; Kim M; Koh ES; Shin SJ; Park CW; Chang YS; Kim HS
PLoS One; 2017; 12(7):e0181757. PubMed ID: 28753620
[TBL] [Abstract][Full Text] [Related]
38. Aliskiren restores renal AQP2 expression during unilateral ureteral obstruction by inhibiting the inflammasome.
Wang W; Luo R; Lin Y; Wang F; Zheng P; Levi M; Yang T; Li C
Am J Physiol Renal Physiol; 2015 Apr; 308(8):F910-22. PubMed ID: 25694485
[TBL] [Abstract][Full Text] [Related]
39. Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction).
Schroten NF; Damman K; Hemmelder MH; Voors AA; Navis G; Gaillard CA; van Veldhuisen DJ; Van Gilst WH; Hillege HL
Am Heart J; 2015 May; 169(5):693-701.e3. PubMed ID: 25965717
[TBL] [Abstract][Full Text] [Related]
40. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
Crespo MJ; Cangiano JL; Altieri PI; Escobales N
J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
